These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 33728523)

  • 1. Tumor levels of the mediators of ErbB2-driven anoikis resistance correlate with breast cancer relapse in patients receiving trastuzumab-based therapies.
    Surette A; Yoo BH; Younis T; Matheson K; Rameh T; Snowdon J; Bethune G; Rosen KV
    Breast Cancer Res Treat; 2021 Jun; 187(3):743-758. PubMed ID: 33728523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ErbB2-driven downregulation of the transcription factor Irf6 in breast epithelial cells is required for their 3D growth.
    Khan IA; Yoo BH; McPhee M; Masson O; Surette A; Dakin-Hache K; Younis T; Bethune G; Rosen KV
    Breast Cancer Res; 2018 Dec; 20(1):151. PubMed ID: 30545388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ErbB2/Her2-dependent downregulation of a cell death-promoting protein BLNK in breast cancer cells is required for 3D breast tumor growth.
    Liu X; Chipurupalli S; Jiang P; Tavasoli M; Yoo BH; McPhee M; Mazinani S; Francia G; Kerbel RS; Rosen KV
    Cell Death Dis; 2022 Aug; 13(8):687. PubMed ID: 35933456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trastuzumab-induced upregulation of a protein set in extracellular vesicles emitted by ErbB2-positive breast cancer cells correlates with their trastuzumab sensitivity.
    Drucker A; Yoo BH; Khan IA; Choi D; Montermini L; Liu X; Jovanovic S; Younis T; Rosen KV
    Breast Cancer Res; 2020 Oct; 22(1):105. PubMed ID: 33023655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ErbB2-dependent downregulation of a pro-apoptotic protein Perp is required for oncogenic transformation of breast epithelial cells.
    Khan IA; Yoo BH; Masson O; Baron S; Corkery D; Dellaire G; Attardi LD; Rosen KV
    Oncogene; 2016 Nov; 35(44):5759-5769. PubMed ID: 27109096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients with HER2-positive early breast cancer receiving adjuvant trastuzumab: clinicopathological features, efficacy, and factors affecting survival.
    Ulas A; Kos T; Avci N; Cubukcu E; Olmez OF; Bulut N; Degirmenci M
    Asian Pac J Cancer Prev; 2015; 16(4):1643-9. PubMed ID: 25743846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p130Cas scaffold protein regulates ErbB2 stability by altering breast cancer cell sensitivity to autophagy.
    Bisaro B; Sciortino M; Colombo S; Camacho Leal MP; Costamagna A; Castellano I; Montemurro F; Rossi V; Valabrega G; Turco E; Defilippi P; Cabodi S
    Oncotarget; 2016 Jan; 7(4):4442-53. PubMed ID: 26716506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).
    Cocco E; Javier Carmona F; Razavi P; Won HH; Cai Y; Rossi V; Chan C; Cownie J; Soong J; Toska E; Shifman SG; Sarotto I; Savas P; Wick MJ; Papadopoulos KP; Moriarty A; Cutler RE; Avogadri-Connors F; Lalani AS; Bryce RP; Chandarlapaty S; Hyman DM; Solit DB; Boni V; Loi S; Baselga J; Berger MF; Montemurro F; Scaltriti M
    Sci Signal; 2018 Oct; 11(551):. PubMed ID: 30301790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration.
    Triulzi T; De Cecco L; Sandri M; Prat A; Giussani M; Paolini B; Carcangiu ML; Canevari S; Bottini A; Balsari A; Menard S; Generali D; Campiglio M; Di Cosimo S; Tagliabue E
    Oncotarget; 2015 Sep; 6(29):28173-82. PubMed ID: 26334217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.
    Canfield K; Li J; Wilkins OM; Morrison MM; Ung M; Wells W; Williams CR; Liby KT; Vullhorst D; Buonanno A; Hu H; Schiff R; Cook RS; Kurokawa M
    Cell Cycle; 2015; 14(4):648-55. PubMed ID: 25590338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer.
    Toomey S; Madden SF; Furney SJ; Fan Y; McCormack M; Stapleton C; Cremona M; Cavalleri GL; Milewska M; Elster N; Carr A; Fay J; Kay EW; Kennedy S; Crown J; Gallagher WM; Hennessy BT; Eustace AJ
    Oncotarget; 2016 Nov; 7(46):75518-75525. PubMed ID: 27776352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers.
    Baldassarre T; Truesdell P; Craig AW
    Breast Cancer Res; 2017 Oct; 19(1):110. PubMed ID: 28974266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER2 Signaling in Breast Cancer.
    Shin I
    Adv Exp Med Biol; 2021; 1187():53-79. PubMed ID: 33983573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of multicellular aggregation in the survival of ErbB2-positive breast cancer cells during extracellular matrix detachment.
    Rayavarapu RR; Heiden B; Pagani N; Shaw MM; Shuff S; Zhang S; Schafer ZT
    J Biol Chem; 2015 Apr; 290(14):8722-33. PubMed ID: 25681438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
    Zsebik B; Citri A; Isola J; Yarden Y; Szöllosi J; Vereb G
    Immunol Lett; 2006 Apr; 104(1-2):146-55. PubMed ID: 16384610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weekly paclitaxel plus carboplatin with or without trastuzumab as neoadjuvant chemotherapy for HER2-positive breast cancer: loss of HER2 amplification and its impact on response and prognosis.
    Wang RX; Chen S; Jin X; Chen CM; Shao ZM
    Breast Cancer Res Treat; 2017 Jan; 161(2):259-267. PubMed ID: 27885439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
    Toomey S; Eustace AJ; Fay J; Sheehan KM; Carr A; Milewska M; Madden SF; Teiserskiene A; Kay EW; O'Donovan N; Gallagher W; Grogan L; Breathnach O; Walshe J; Kelly C; Moulton B; Kennedy MJ; Gullo G; Hill AD; Power C; Duke D; Hambly N; Crown J; Hennessy BT
    Breast Cancer Res; 2017 Jul; 19(1):87. PubMed ID: 28750640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance.
    Huang X; Wang S; Lee CK; Yang X; Liu B
    Cancer Lett; 2011 Aug; 307(1):72-79. PubMed ID: 21497990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer.
    Hori A; Shimoda M; Naoi Y; Kagara N; Tanei T; Miyake T; Shimazu K; Kim SJ; Noguchi S
    Breast Cancer Res; 2019 Aug; 21(1):88. PubMed ID: 31387614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.